

Final Appraisal Recommendation

Advice No: 3314 – October 2014

**Alogliptin/metformin (Vipdomet[®]▼) 12.5 mg/1,000 mg
film-coated tablets**

Limited submission by Takeda UK Ltd

Recommendation of AWMSG

Alogliptin/metformin (Vipdomet[®]▼) is recommended as an option for restricted use for dual oral therapy within NHS Wales.

Alogliptin/metformin (Vipdomet[®]▼) should be restricted for use in the following circumstances within its licensed indication for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus:

- **As an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin as separate tablets.**

Alogliptin/metformin (Vipdomet[®]▼) is not recommended for use within NHS Wales outside of these circumstances.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1271), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Marketing authorisation holder on first issue	Takeda UK Ltd
Date of first issue	October 2014
Last reviewed	December 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3314:
Alogliptin/metformin (Vipdomet[®]▼) 12.5 mg/1,000 mg film-coated tablets. October 2014.